-
Today's pharmaceutical business stocks have changed, and a large number of pharmaceutical companies such as Yifeng Pharmacy, Yixintang, and Jianzhijia have risen to the limit
Time of Update: 2023-02-03
According to the data, Yifeng Pharmacy's main business is the chain retail business of medicines, health products, health foods, medical devices, personal care products and health-related daily convenience products.
-
When will the price of perilla leaves that have skyrocketed 10 times, when will the market fall?
Time of Update: 2023-02-03
Guangzhou Maoming perilla leaf business introduced that the planting volume of perilla this year is not large, the production of new end in mid-September, when the supply of goods is better, farmers are basically selling fresh goods, the price of the whole plant is about 1 yuan / jin; In the early stage, there were also farmers picking perilla leaves for sale, and the price at that time was around 30 yuan.
-
"Category B and B pipe": What changes have been brought about by prevention and control measures? How can risks be prevented?
Time of Update: 2023-02-03
Popularize the knowledge of the prevention and control of new coronavirus infection, advocate personal protection, adhere to good hygiene habits such as wearing masks and washing hands frequently, help the public use medicine rationally, seek medical treatment correctly, and maintain a peaceful attitude and optimism.
-
Ibuprofen pharmacy sold more than 1.5 billion, this company won the "sales crown"!
Time of Update: 2023-02-03
com: China's urban physical pharmacy drug terminal competition pattern In 2022, it is expected that the sales of the top 6 varieties of anti-inflammatory and anti-rheumatic drugs will exceed 100 million yuan, ranking consistent with 2021.
-
Pharmaceutical stocks changed, Huahai Pharmaceutical, Haisco and other pharmaceutical companies rose to the limit
Time of Update: 2023-02-03
The data shows that in terms of the capital flow data of Huahai Pharmaceutical on December 28, the net inflow of main funds was 316 million yuan, accounting for 20.
-
Greek authorities will check for cardiovascular diseases free of charge in 2023 and 5.5 million people are expected to benefit
Time of Update: 2023-02-03
Greece's Spyros Doxiadis public health program, which is expected to begin in early 2023, includes free cardiovascular disease prevention and treatment examinations for all citizens between the ages of 30 and 70, according to the Greek newspaper.
-
The National Health Commission issued the standards set by the National Center for Rare Diseases
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];In order to further promote the expansion of high-quality medical resources and balanced regional layout, lead the development of medical science and the improvement of overall medical service capabilities, the General Office of the National Health Commission recently issued the "Standards for the Setting of National Rare Disease Medical Centers".
-
Guangzhou GPO platform opened the Hong Kong and Macao Pharmacy and Equipment Procurement Zone
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The reporter learned from Guangzhou Exchange Group on the 29th that Guangzhou Drug and Medical Consumables Procurement Platform (hereinafter referred to as "Guangzhou GPO Platform") under Guangzhou Exchange Group recently set up a Hong Kong and Macao Drug Procurement Zone, and has completed the work of hanging the network of two specifications of cardinib, which are urgently needed to import Hong Kong and Macao drugs for clinical purposes.
-
Guangdong pharmaceutical companies urgently resumed production of ibuprofen tablets with a daily production capacity of 3 million tablets
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On the 29th, in the production workshop of Baiyunshan Pharmaceutical General Factory of Guangzhou Pharmaceutical Group located in Baiyun District, Guangzhou, the roar of machines echoed in my ears.
-
Chia Tai Tianqing's first ADC came, storming the 200 billion market
Time of Update: 2023-02-03
Data statistics as of December 27, if there is any omission, welcome to correct!Recently, CT Tianqing Pharmaceutical's self-developed Class 1 new drug TQB2102 for injection has obtained the implied license of clinical trials and is intended to be used for the treatment of advanced malignant tumors.
-
The net outflow of 12 shares, including Zhongsheng Pharmaceutical and China Pharmaceutical, exceeded 100 million yuan
Time of Update: 2023-02-03
In addition, China Pharmaceutical Financing and Securities Lending Information shows that on December 27, 2022, the net repayment of financing was 12.
In addition, China Pharmaceutical Financing and Securities Lending Information shows that on December 27, 2022, the net repayment of financing was 12.
-
The concept of pharmaceutical CRO strengthened, and individual stocks rose! Institution: optimistic about the high prosperity of the industry
Time of Update: 2023-02-03
At the same time, the company continues to increase investment in research and development, and forward-looking layout in the field of cutting-edge technology of biomedicine.
At the same time, the company continues to increase investment in research and development, and forward-looking layout in the field of cutting-edge technology of biomedicine.
-
13 pharmaceutical stocks such as Aier Eye Science had a net inflow of more than 30 million yuan
Time of Update: 2023-02-03
In terms of securities financing, Changchun High-tech repaid 13,500 shares on December 27, and sold 21,200 shares on margin trading, with a selling amount of 3,647,000 yuan according to the closing price of the day, accounting for 0.
-
After the implementation of the "Class B tube" of the new crown, how to do the prevention and treatment of traditional Chinese medicine? Official response
Time of Update: 2023-02-03
Since the outbreak of the epidemic, in the practice of medical treatment at all levels, China has always adhered to the combination of traditional Chinese medicine and Western medicine, paid equal at
-
The State Food and Drug Administration established the second Technical Committee for Medical Device Classification
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];In order to strengthen the technical support for the classification and management of medical devices, in accordance with the relevant provisions of the Regulations on the Supervision and Administration of Medical Devices, the Rules for the Classification of Medical Devices and the Rules for the Classification of In Vitro Diagnostic Reagents, the State Medical Products Administration decided to establish the second Technical Committee for the Classification of Medical Devices.
-
Market demand surged, and the "oximeter" concept stock rose sharply today
Time of Update: 2023-02-03
The relevant person in charge of Kangtai Medical said, "Because the oximeter can monitor the blood oxygen saturation in real time and detect abnormal respiratory system as soon as possible, the market demand for oximeter is strong in the near future.
-
The current inflection point of pharmaceutical stocks has arrived! Many pharmaceutical companies such as Zai Lab and Junshi Biologics rose sharply
Time of Update: 2023-02-03
On the news, new data from the Stock Exchange shows that on December 22, JPMorgan Chase & Co. increased its holdings in Zai Lab again, buying about 13 million shares on the same day, and the proportion of good positions rose from 8.
-
"Yang" to see a doctor, take medicine, how to be reimbursed by medical insurance? Many places have made clear →
Time of Update: 2023-02-03
With the optimization and adjustment of China's epidemic prevention and control measures, the official announced that from January 8, the new coronavirus infection will be implemented "Class B tube",
-
Ministry of Industry and Information Technology: Organized more than 750 key medical materials enterprises to expand production capacity
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Wang Jiangping, vice minister of the Ministry of Industry and Information Technology of China, introduced on the 29th that more than 750 key enterprises in key provinces such as Shandong, Hubei, Liaoning, Henan, Shanxi and Hebei have been organized to continuously improve the production and supply capacity of key medical materials.
-
In 2023, the market size of China's pharmaceutical intermediates may exceed 200 billion yuan! Key enterprise predictive analytics is coming
Time of Update: 2023-02-03
Senxuan Pharmaceutical recently said in an institutional survey that in the first three quarters of 2022, the company's production and operation were stable, and both revenue and profit increased, of which operating income increased by 24% year-on-year, and net profit attributable to listed companies increased by 38.
